miRNA Sequencing And Assay Market Research Report 2023: Global Size, Share & Trends Analysis and Forecasts to 2030 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “miRNA Sequencing And Assay Market Size, Share & Trends Analysis Report By Product & Service (Library Preparation Kits), By Technology, By Workflow, By Application, By End-use, By Region, And Segment Forecasts, 2023 – 2030” report has been added to ResearchAndMarkets.com’s offering.

The global miRNA sequencing and assay market size is expected to reach USD 823.5 Million by 2030, registering a CAGR of 13.3% from 2023 to 2030.

For instance, various research studies stated that miRNAs can be efficiently used as biomarkers in the prognosis and diagnosis of cancer (cervical, ovarian, and breast), sepsis, cardiovascular diseases, and nervous system conditions. Thus, miRNA sequence analysis is significantly employed for gene regulation analysis in clinical disorders. For instance, an article published in frontiers, in March 2022, stated that blood-based miRNA biomarkers could be used to correlate brain-based miRNA expression.

The COVID-19 pandemic has enhanced the usage of miRNA to identify the presence of coronavirus. miRNA biomarkers have potential application to indicate and diagnose the COVID-19 severity. It plays a significant role in immune response, viral proliferation, replication of infected cells, and cardiovascular dysfunction. In addition, plasma recovered from COVID-19 patients is rich in antibodies and antiviral miRNAs. It has been utilized to treat COVID-19-infected patients. This has resulted in increasing research studies that focus on the miRNA sequence analysis from the patient as well as the virus.

Prominent players such as PerkinElmer Inc.; Illumina, Inc.; and Qiagen offer innovative sequencing products for several clinical applications. Furthermore, these companies have entered into several strategic initiatives with research institutes to expand the sequencing application in research studies. For instance, in January 2022, BIORCHESTRA, a South Korean biopharmaceutical company, entered into a partnership agreement with SK Biopharmaceuticals to accelerate research and development into novel therapeutic compounds that target miRNAs.

Key market players are involved in the development of new tools, instruments, and kits with high specificity and reproducibility, which is fueling the market growth. For instance, in October 2019, TriLink BioTechnologies introduced two primer sets for its CleanTag kit. Thermo Fisher Scientific’s sequencer platform can prepare small RNA libraries using these new Ion Torrent Convert barcode primer sets. Such launches are expected to boost market growth.

miRNA Sequencing And Assay Market Report Highlights

• The products segment dominated the market with the largest revenue share of around 80% in 2022. This is due to the presence of several key companies that offer a broad range of consumables, kits, and instruments for specific applications
• By technology, the sequencing by synthesis segment dominated the market with the largest revenue share of over 32% in 2022. This is due to its fast turnaround time, high sensitivity, and high throughput. Moreover, it plays a key role in the mutation detection of tumor tissue, which helps to develop personalized therapies
• By workflow, the sequencing segment dominated the market with the largest revenue share of over 50% in 2022 and is expected to grow at the fastest CAGR of 14.1% over the forecast period as it is the most important step in the workflow. It has become a key research tool in biological research and several disease diagnoses
• By application, the cancer segment dominated the market and accounted for the largest revenue share of over 35% in 2022. Several ongoing research in cancer using miRNA as a biomarker to study the prognosis and diagnosis of cancer to develop new therapies is contributing to the segment growth
• By end-use, the research and academic institutes segment dominated the market and accounted for the largest revenue share of over 50% in 2022. The growth is attributed to the increased R&D studies conducted by academic institutes using miRNA sequencing techniques
• Asia Pacific is expected to grow at the fastest CAGR of 15.4% during the forecast period. This is due to the growing healthcare infrastructure, significant targeted population, and high unmet clinical needs

Company Profiles

• Thermo Fisher Scientific, Inc.
• Illumina, Inc.
• QIAGEN
• PerkinElmer, Inc
• Abcam plc
• New England Biolabs
• Takara Bio Inc.
• Lexogen GmbH
• Norgen Biotek Corp.
• Maravai LifeSciences
• HTG Molecular Diagnostics, Inc.
• Meridian Bioscience, Inc.
• System Biosciences, LLC

Key Attributes:

Report Attribute	Details
No. of Pages	120
Forecast Period	2022 – 2030
Estimated Market Value (USD) in 2022	$304.3 Million
Forecasted Market Value (USD) by 2030	$823.5 Million
Compound Annual Growth Rate	13.3%
Regions Covered	Global

Key Topics Covered:

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

2.1. Market Outlook

2.2. Segment Outlook

2.3. Competitive Insights

Chapter 3. miRNA Sequencing And Assay Market Variables, Trends & Scope

3.1. Market Lineage Outlook

3.1.1. Parent market outlook

3.1.2. Related/ancillary market outlook

3.2. Penetration & Growth Prospect Mapping

3.3. Market Dynamics

3.3.1. Market driver analysis

3.3.2. Market restraint analysis

3.4. miRNA Sequencing And Assay Market Analysis Tools

3.4.1. Industry Analysis – Porter’s

3.4.2. PESTEL Analysis

Chapter 4. miRNA Sequencing And Assay: Product & Service Estimates & Trend Analysis

4.1. miRNA Sequencing And Assay Market: Key Takeaways

4.2. miRNA Sequencing And Assay Market: Movement & Market Share Analysis, 2022 & 2030

4.3. Products

4.3.1. Products market estimates and forecasts, 2018 to 2030 (USD Million)

4.3.2. Library preparation kits

4.3.3. Sequencing consumables

4.3.4. Instruments

4.4. Services

Chapter 5. MiRNA Sequencing And Assay: Technology Estimates & Trend Analysis

5.1. MiRNA Sequencing And Assay Market: Key Takeaways

5.2. MiRNA Sequencing And Assay Market: Movement & Market Share Analysis, 2022 & 2030

5.3. Sequencing by synthesis

5.4. Sequencing By Oligonucleotide Ligation and Detection (SOLiD)

5.5. Nanopore Sequencing

5.6. Sanger Sequencing

5.7. Single molecule real – time (SMRT) Sequencing

Chapter 6. MiRNA Sequencing And Assay: Workflow Estimates & Trend Analysis

6.1. MiRNA Sequencing And Assay Market: Key Takeaways

6.2. MiRNA Sequencing And Assay Market: Movement & Market Share Analysis, 2022 & 2030

6.3. Library Preparation

6.4. Sequencing

6.5. Data analysis & storage

Chapter 7. MiRNA Sequencing And Assay: Application Estimates & Trend Analysis

7.1. MiRNA Sequencing And Assay Market: Key Takeaways

7.2. MiRNA Sequencing And Assay Market: Movement & Market Share Analysis, 2022 & 2030

7.3. Cancer

7.4. Polyglutamine Diseases

7.5. Autoimmune Disease

7.6. Schizophrenia

Chapter 8. MiRNA Sequencing And Assay: End Use Estimates & Trend Analysis

8.1. MiRNA Sequencing And Assay Market: Key Takeaways

8.2. MiRNA Sequencing And Assay Market: Movement & Market Share Analysis, 2022 & 2030

8.3. Pharmaceutical & Biotechnology Industry

8.4. Research & Academic Institutes

8.5. Others

Chapter 9. MiRNA Sequencing And Assay: Regional Estimates & Trend Analysis

9.1. Regional Outlook

9.2. MiRNA Sequencing And Assay Market by Region: Key Takeaway

Chapter 10. Competitive Landscape

10.1. Recent Developments & Impact Analysis, By Key Market Participants

10.2. Market Participant Categorization

10.2.1. Company overview

10.2.2. Financial performance

10.2.3. Product benchmarking

10.2.4. Strategic initiatives

For more information about this report visit https://www.researchandmarkets.com/r/46m20b

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900